Summary: In this episode, Shivu and Kenny delve into the evolving landscape of GLP-1 drugs, particularly focusing on the recent advancements in oral formulations and their potential applications beyond diabetes and obesity, including CNS diseases and addiction. They discuss the challenges of adherence, the mechanisms of action, and the economic implications of these therapies, while also highlighting the importance of early intervention in treatment. The conversation emphasizes the promising future of GLP-1s in various therapeutic areas and the ongoing research that will shape their role in healthcare.

References:

• Shivu's recent substack post discussing GLP-1s for CNS disease: https://www.bigpharmasharma.com/p/what-2025-holds-for-glp-1s-in-brain
• GLP-1 Growth Graph: Zheng, Z., Zong, Y., Ma, Y. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024).

Contact us:

• Questions?: drugdealinpod@gmail.com
• Follow us on X: ⁠https://x.com/DrugDealinPod⁠
• Follow Shivu : ⁠https://linktr.ee/shivusharma⁠
• Subscribe to Shivu's newsletter: https://www.bigpharmasharma.com/

• Follow Kenny: ⁠https://www.linkedin.com/in/kennylalwani/⁠

Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.

Chapters

00:00 Introduction to GLP-1s

02:52 The Evolution of Oral GLP-1s

06:26 Challenges in Patient Adherence

10:34 Exploring CNS Impacts of GLP-1s

14:44 Mechanisms of Action in CNS Diseases

19:13 Potential in Addiction Treatment

24:23 Future Directions and Research Opportunities

30:20 Exploring the Mechanisms of New Medications

35:16 Long-term Use and Dosing Challenges

39:57 Promising Data in Addiction Treatment

43:56 The Future of CNS and Metabolic Dysfunction Treatments

50:44 The Path Forward in Drug Development

54:50 Outro